Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA
July 2, 2021
Paris, France, 2nd July 2021 – 7 am CEST – Advicenne (Euronext: ADVIC), a specialty pharmaceutical company
dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases,
is pleased to announce that the Medicines & Healthcare products Regulatory Agency (MHRA) has today granted
marketing authorisation for Sibnayal™ (ADV7103) in the UK, for the treatment of distal renal tubular acidosis
(dRTA).